MedTrace Logo

AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma

NCT01200108 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-11-15

No results posted yet for this study

Summary

The goal of treatment with AICS is weaning from oral corticosteroids, i.e. a reduction of the oral corticosteroid dose. An anticipated treatment benefit of AICS is a reduction of oral corticosteroid dose and stability/improvement of clinical parameters related to asthma in the targeted subject population. Ultimately, the goal is to free subjects with severe asthma from the burden of chronic oral steroid therapy.

Conditions

Interventions

DRUG

Budesonide

DRUG

Budesonide

DRUG

Budesonide

Sponsors & Collaborators

  • Activaero GmbH

    lead INDUSTRY

Principal Investigators

  • Peter Kardos, MD · Peter Kardos

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • Germany
  • Poland
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01200108 on ClinicalTrials.gov